Flávia de Paiva Santos Rolim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Flávia de Paiva Santos Rolim has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Fernanda Martins Maia Carvalho
Movement Disorders Division, Department of Neurology Hospital Geral de Fortaleza Fortaleza Brazil
3 shared publications - Ana Silvia Sobreira Lima Verde
Movement Disorders Division, Department of Neurology Hospital Geral de Fortaleza Fortaleza Brazil
2 shared publications - Denise Maria Meneses Cury Portela
Afya Centro Universitário Uninovafapi, Teresina PI, Brazil
2 shared publications - Milena Sales Pitombeira
Universidade de São Paulo, Faculdade de Medicina, Hospital das Clínicas, Departamento de Radiologia e Oncologia, Divisão e Laboratório de Medicina Nuclear (LIM 43), São Paulo SP, Brazil
2 shared publications - Norberto Anízio Ferreira Frota
Hospital Geral de Fortaleza
2 shared publications - Paula Camila Alves de Assis Pereira Matos
Movement Disorders Division, Department of Neurology Hospital Geral de Fortaleza Fortaleza Brazil
2 shared publications
Latest Publications
- Open Access
- 16 September 2026
- Published by Wiley in Movement Disorders Clinical Practice
Opsoclonus‐Myoclonus‐Ataxia Revealing Underlying Neuromyelitis Optica Spectrum Disorder
- 16 September 2026
- Published by Wiley in Movement Disorders Clinical Practice
Open AccessOpsoclonus‐Myoclonus‐Ataxia Revealing Underlying Neuromyelitis Optica Spectrum Disorder
- Open Access
- 23 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (04) , 001-004
Ozzy Osbourne and Parkinson's disease: from darkness to awareness
Ozzy Osbourne, the legendary frontman of Black Sabbath, publicly revealed his diagnosis of Parkinson's disease (PD) in 2020, offering visibility to a complex neurodegenerative condition. His case, later linked to a mutation in the PARK2 (parkin) gene, presented atypically with a later age of onset, contributing to ongoing discussions about the phenotypic variability of genetic forms of PD. Beyond medical narratives, Osbourne's openness and philanthropy—culminating in a benefit concert that raised $190 million for Parkinson's and pediatric charities—played a transformative role in destigmatizing the disease. This article explores the scientific and social impact of Osbourne's disclosure, highlighting the role of PARK2 in mitochondrial homeostasis, synaptic integrity, and tumor suppression. We also examine his pursuit of experimental stem cell therapy, discussing its scientific basis, ethical considerations, and current clinical research landscape.
- 23 March 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (04) , 001-004
Open AccessOzzy Osbourne and Parkinson's disease: from darkness to awareness
Ozzy Osbourne, the legendary frontman of Black Sabbath, publicly revealed his diagnosis of Parkinson's disease (PD) in 2020, offering visibility to a complex neurodegenerative condition. His case, later linked to a mutation in the PARK2 (parkin) gene, presented atypically with a later age of onset, contributing to ongoing discussions about the phenotypic variability of genetic forms of PD. Beyond medical narratives, Osbourne's openness and philanthropy—culminating in a benefit concert that raised $190 million for Parkinson's and pediatric charities—played a transformative role in destigmatizing the disease. This article explores the scientific and social impact of Osbourne's disclosure, highlighting the role of PARK2 in mitochondrial homeostasis, synaptic integrity, and tumor suppression. We also examine his pursuit of experimental stem cell therapy, discussing its scientific basis, ethical considerations, and current clinical research landscape.
- 23 September 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 140, 108058
Cognitive and psychiatric profile in a Brazilian case of SNCA duplication
- 23 September 2025
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 140, 108058
Cognitive and psychiatric profile in a Brazilian case of SNCA duplication
- Open Access
- 2 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (3) , 600-610
Movement Disorders in Neuromyelitis Optica Spectrum Disorder: A Systematic Review
Background: Several movement disorders (MD) have been reported to occur in neuromyelitis optica spectrum disorder (NMOSD). No extensive review has addressed the whole spectrum of MD in NMOSD. Objective: This article aims to review MD in NMOSD, describing its prevalence and features. Methods: A systematic review and prevalence meta‐analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) reporting guidelines. We included articles on NMOSD patients with MD as defined by the 2015 international consensus criteria. Meta‐analysis was considered feasible if the prevalence of certain MDs was evaluated for at least 4 studies with more than 5 patients. Results: Ninety‐six articles were selected from an initial pool of 5441, involving 1751 patients, of whom 487 had MD. The prevalence of anti‐aquaporin‐4 antibodies (AQP4‐IgG) was 79.9% in general and 78.7% in NMOSD‐MD patients. Tonic spasms/paroxysmal dystonia and ataxia were the most prevalent MD in NMOSD, with 39% and 26% prevalence, respectively. Tremor, parkinsonism, myoclonus, chorea, and other hyperkinetic disorders were more rarely reported. Conclusions: A wide range of MDs in NMOSD were found, each with distinct features and frequency in literature. This knowledge might help to identify patients with NMOSD, which presents MD as a clinical feature and improves outcomes.
- 2 September 2025
- Published by Wiley in Movement Disorders Clinical Practice
- Vol. 13 (3) , 600-610
Open AccessMovement Disorders in Neuromyelitis Optica Spectrum Disorder: A Systematic Review
Background: Several movement disorders (MD) have been reported to occur in neuromyelitis optica spectrum disorder (NMOSD). No extensive review has addressed the whole spectrum of MD in NMOSD. Objective: This article aims to review MD in NMOSD, describing its prevalence and features. Methods: A systematic review and prevalence meta‐analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) reporting guidelines. We included articles on NMOSD patients with MD as defined by the 2015 international consensus criteria. Meta‐analysis was considered feasible if the prevalence of certain MDs was evaluated for at least 4 studies with more than 5 patients. Results: Ninety‐six articles were selected from an initial pool of 5441, involving 1751 patients, of whom 487 had MD. The prevalence of anti‐aquaporin‐4 antibodies (AQP4‐IgG) was 79.9% in general and 78.7% in NMOSD‐MD patients. Tonic spasms/paroxysmal dystonia and ataxia were the most prevalent MD in NMOSD, with 39% and 26% prevalence, respectively. Tremor, parkinsonism, myoclonus, chorea, and other hyperkinetic disorders were more rarely reported. Conclusions: A wide range of MDs in NMOSD were found, each with distinct features and frequency in literature. This knowledge might help to identify patients with NMOSD, which presents MD as a clinical feature and improves outcomes.
- Open Access
- 28 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (11) , 001-007
Deep brain stimulation for dystonia: outcomes from a Brazilian cohort
Deep brain stimulation (DBS) is a treatment for dystonia, with most trials conducted in developed countries. Data from developing countries like Brazil are limited. To evaluate the landscape of DBS for dystonia in Brazil, assessing motor outcomes compared with the existing literature. A retrospective multicenter cohort study was conducted via medical record review. Demographics and motor outcomes were collected and analyzed using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) from patients across four of Brazil's five macro-regions. The cohort included 60 patients (44.3% female), with DBS primarily targeting the globus pallidus internus (73.3%) or subthalamic nucleus (18.3%). The BFMDRS motor scores decreased from 63.0 ± 26.2 (n = 24) at baseline to 36.7 ± 24.6 at 1-year post-DBS (n = 22, p = 0.0018) and 43.6 ± 35.0 at the last assessment (n = 13, p = 0.0327). The use of DBS yielded significant, sustained motor improvements, consistent with developed countries, highlighting its feasibility and effectiveness in Brazil within diverse healthcare settings.
- 28 July 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (11) , 001-007
Open AccessDeep brain stimulation for dystonia: outcomes from a Brazilian cohort
Deep brain stimulation (DBS) is a treatment for dystonia, with most trials conducted in developed countries. Data from developing countries like Brazil are limited. To evaluate the landscape of DBS for dystonia in Brazil, assessing motor outcomes compared with the existing literature. A retrospective multicenter cohort study was conducted via medical record review. Demographics and motor outcomes were collected and analyzed using the Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS) from patients across four of Brazil's five macro-regions. The cohort included 60 patients (44.3% female), with DBS primarily targeting the globus pallidus internus (73.3%) or subthalamic nucleus (18.3%). The BFMDRS motor scores decreased from 63.0 ± 26.2 (n = 24) at baseline to 36.7 ± 24.6 at 1-year post-DBS (n = 22, p = 0.0018) and 43.6 ± 35.0 at the last assessment (n = 13, p = 0.0327). The use of DBS yielded significant, sustained motor improvements, consistent with developed countries, highlighting its feasibility and effectiveness in Brazil within diverse healthcare settings.
- Open Access
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (07) , 001-004
High-intensity focused ultrasound (HIFU) versus deep brain stimulation (DBS) for refractory tremor: team DBS
Deep brain stimulation (DBS) has been widely accepted as a powerful tool capable of suppressing tremor by modulating the neuronal circuitry, with long-term adaptability and a profile of low adverse effects. It has been the primary treatment for refractory tremor for decades, with sustained long-term efficacy. Recently, magnetic resonance-guided high-frequency focused ultrasound (HIFU) has emerged as an alternative, prompting comparisons between these approaches. Deep brain stimulation offers long-lasting tremor control in Parkinson's disease (PD) and essential tremor (ET). In addition, it enables us to advance our understanding of brain circuits by integrating neuroimaging, electrophysiology, and connectomics data to map the best stimulation spots. Technologies such as adaptive and directional DBS enable real-time adjustments and greater precision, optimizing results and minimizing adverse effects. Although HIFU shows promising results, it remains an ablative and non-adjustable therapy, contrasting with DBS's dynamic and customizable advances.
- 20 June 2025
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 83 (07) , 001-004
Open AccessHigh-intensity focused ultrasound (HIFU) versus deep brain stimulation (DBS) for refractory tremor: team DBS
Deep brain stimulation (DBS) has been widely accepted as a powerful tool capable of suppressing tremor by modulating the neuronal circuitry, with long-term adaptability and a profile of low adverse effects. It has been the primary treatment for refractory tremor for decades, with sustained long-term efficacy. Recently, magnetic resonance-guided high-frequency focused ultrasound (HIFU) has emerged as an alternative, prompting comparisons between these approaches. Deep brain stimulation offers long-lasting tremor control in Parkinson's disease (PD) and essential tremor (ET). In addition, it enables us to advance our understanding of brain circuits by integrating neuroimaging, electrophysiology, and connectomics data to map the best stimulation spots. Technologies such as adaptive and directional DBS enable real-time adjustments and greater precision, optimizing results and minimizing adverse effects. Although HIFU shows promising results, it remains an ablative and non-adjustable therapy, contrasting with DBS's dynamic and customizable advances.
- Open Access
- 1 September 2022
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 16 (3) , 361-364
Diagnostic approach in a patient with Creutzfeldt-Jakob disease
Prion diseases are an important cause of rapidly progressive dementias. Among them, the most common is sporadic Creutzfeldt-Jakob disease (CJD). It is a rare and incurable disease, with rapid progression to death. Objective: To describe the diagnostic approach of a patient with Creutzfeldt-Jakob disease. Methods: The diagnosis is established through the clinical picture associated with characteristic changes in the brain magnetic resonance imaging, the electroencephalogram, and analysis of specific changes in the cerebrospinal fluid. Results: The present report describes the case of a 53-year-old patient in the city of Fortaleza-CE. The diagnosis was made based on the clinical condition and through diagnostic tests, including 14-3-3 protein and RT QUIC analysis. Differential diagnosis was performed with other rapidly progressive causes, such as infectious and immune-mediated diseases. Conclusions: The diagnosis of probable sporadic CJD was established.
- 1 September 2022
- Published by FapUNIFESP (SciELO) in Dementia & Neuropsychologia
- Vol. 16 (3) , 361-364
Open AccessDiagnostic approach in a patient with Creutzfeldt-Jakob disease
Prion diseases are an important cause of rapidly progressive dementias. Among them, the most common is sporadic Creutzfeldt-Jakob disease (CJD). It is a rare and incurable disease, with rapid progression to death. Objective: To describe the diagnostic approach of a patient with Creutzfeldt-Jakob disease. Methods: The diagnosis is established through the clinical picture associated with characteristic changes in the brain magnetic resonance imaging, the electroencephalogram, and analysis of specific changes in the cerebrospinal fluid. Results: The present report describes the case of a 53-year-old patient in the city of Fortaleza-CE. The diagnosis was made based on the clinical condition and through diagnostic tests, including 14-3-3 protein and RT QUIC analysis. Differential diagnosis was performed with other rapidly progressive causes, such as infectious and immune-mediated diseases. Conclusions: The diagnosis of probable sporadic CJD was established.